Yesterday it was reported that the CBO of Dicerna Pharma (NASDAQ: DRNA), James Weissman, exercised options to buy 14,680 DRNA shares at $3.42 a share, for a total transaction value of $50.21K.
Following this transaction James Weissman’s holding in the company was increased by 149.8% to a total of $379.9K.
See today’s analyst top recommended stocks >>
Based on Dicerna Pharma’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $1.55 million and GAAP net loss of $35.64 million. In comparison, last year the company earned revenue of $252K and had a GAAP net loss of $15.23 million. Currently, Dicerna Pharma has an average volume of 198.4K. The Company has a Price to Book ratio of 12.7063.
Eight different firms, including Barclays and Cowen & Co., currently also have a Buy rating on the stock. Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $18.50, reflecting a -16.1% downside.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases using its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas.
